Document is current
Any future updates will be listed below
-
Authors
Buttgereit, Frank https://orcid.org/0000-0003-2534-550X
Palmowski, Andriko
Bond, Milena https://orcid.org/0000-0002-5400-2955
Adami, Giovanni https://orcid.org/0000-0002-8915-0755
Dejaco, Christian https://orcid.org/0000-0002-0173-0668
- License Information
-
More Information
Article History
Accepted: 25 April 2024
First Online: 3 June 2024
Competing interests
: F.B. declares that he has received consultancy fees, honoraria, travel expenses and grant support from AbbVie, Amgen, Horizon Therapeutics and Pfizer (all unrelated to this manuscript). The work of F.B. in the ongoing Rh-GIOP study (Glucocorticoid-induced osteoporosis in patients with chronic inflammatory rheumatic diseases or psoriasis; NCT02719314) is or was supported by joint funding from AbbVie, Amgen, Almirall, Biogen, BMS, Chugai, Galapagos, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi. A.P. has received consulting fees from Novartis (unrelated to this manuscript). G.A. declares that he has received consulting/speaker’s fees from Eli Lilly, Pfizer, Theramex, Galapagos, BMS, Fresenius Kabi, Amgen and UCB (all unrelated to this manuscript). M.B. declares that he has received consulting/speaker’s fees from AbbVie (unrelated to this manuscript). C.D. has received consulting/speaker’s fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos, Sparrow and Sanofi, and grant support from AbbVie and Novartis (all unrelated to this manuscript).
